This is a 24-week Phase 3, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of three doses of crofelemer, a natural compound. Eligible volunteers will
be randomized to receive crofelemer or placebo administered orally twice daily for the initial
placebo-controlled treatment phase; thereafter for 20 weeks all participants will receive
crofelemer. Participants will be compensated for their time and inconvenience for up to $400.
Basic Study Requirements:
- Male or female aged 18 years or older
- HIV-1 infection confirmed by standard serological tests and/or viral load
- History of diarrhea of at least 1 month's duration
This is a 48-week, Phase 3, randomized, double-blinded, placebo-controlled study evaluating the effects
of vicriviroc in combination with an optimized background regimen. The investigational drug, vicriviroc,
inhibits entry of HIV into cells and is active against a variety of HIV strains, including antiretroviral-resistant
strains. Eligible volunteers will be randomized in a 2:1 ratio to receive vicriviroc or placebo for 48 weeks. Participants
will be compensated for their time and inconvenience.
Basic Study Requirements
- HIV-1-positive adult at least 18 years of age
- Viral load greater than 1,000 copies/ml
- Must be antiretroviral-experienced
If vicriviroc at the dosage studied proves to be safe and effective, study volunteers who successfully complete
48 weeks of treatment and for whom it is medically appropriate will be offered vicriviroc free of charge until the drug
is commercially available. Volunteers will not be compensated for this part of the study.
This is a 10-week Phase 2/3 proof-of-concept, randomized, double-blinded, placebo-controlled study to evaluate the
effects of Punica granatum (pomegranate) juice on the indices of quality of life and cardiac health in
HIV-1-positive volunteers. Eligible volunteers will be randomized in a 1:1:1 ratio to receive one of two formulations
of pomegranate juice (once daily, 8-ounce) or a placebo. Volunteers who complete participation in the 10 week study
and were in the placebo group will be re-randomized to receive one of two pomegranate juice formulations for another
8-weeks. Volunteers will be compensated $25 per visit for their time and inconvenience..
Basic Study Requirements
- HIV-1-positive adult at least 18 years of age
- CD4 cell count greater than 350 cells/mm 3
- Treatment naïve or not currently on antiretroviral therapy for at least 90 days prior to the screening visit
- No current use of immune modulating therapies (i.e., IL-2, vaccine, Interferon gamma)
This study will help researchers to develop a rectal microbicide, a new HIV prevention strategy to be used during
anal intercourse. This one visit study involves a computer-assisted interview focusing on the behaviors surrounding
receptive anal intercourse, an anorectal examination, along with testing for sexually transmitted infections in compliance
with local, state, and federal laws regarding sexually transmitted diseases. This study does not involve any medication or
experimental procedures. Volunteers will be compensated $100 for one completed study visit for their time and inconvenience.
Basic Study Requirements
- Males or females at least 18 years of age
- HIV-negative or HIV-positive
- Either practices or does not practice receptive anal intercourse
